Parallel Advisors’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
Parallel Advisors's ACRS Position: Q3 2026 in Review
Parallel Advisors held its Aclaris Therapeutics (ACRS) position steady in Q3 2026 at 357 shares worth $1.88K. The position accounts for ﹤0.01% of the portfolio, ranked #3658.
Parallel Advisors first reported a position in ACRS in Q3 2018 and has held it in 21 quarters since. The position peaked at $42K in Q3 2018. 35 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.
- Parallel Advisors held 357 shares of Aclaris Therapeutics worth $1.88K as of Q3 2026.
- Parallel Advisors left its Aclaris Therapeutics share count unchanged in Q3 2026.
- Aclaris Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3658 holding.
- Parallel Advisors first reported a position in Aclaris Therapeutics in Q3 2018 and has held it in 21 quarters since.
- Parallel Advisors's Aclaris Therapeutics position peaked at $42K in Q3 2018.
- 35 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.
Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.